(Total Views: 62)
Posted On: 11/12/2024 1:47:03 PM
Post# of 35599
$CBDW acquisition target Adnexus Biotechnologies Inc. is delighted to reveal the completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. https://finance.yahoo.com/news/1606-corp-targ...00778.html
(0)
(0)
Scroll down for more posts ▼
